SCHEMBL6315559

SCHEMBL6315559

Nc1ccc(CCO)cc1I

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.47
GAA P10253 2/20 0.47
MAPT P10636 2/20 0.47
ALDH1A1 P00352 1/20 0.47
ALOX5 P09917 1/20 0.47
BACE1 P56817 1/20 0.47
CA2 P00918 3/20 0.41
ADRB2 P07550 1/20 0.39
TBXA2R P21731 1/20 0.39
CA12 O43570 2/20 0.38
CA1 P00915 2/20 0.38
CA4 P22748 2/20 0.38
CA6 P23280 2/20 0.38
CA5A P35218 2/20 0.38
CA7 P43166 2/20 0.38
CA9 Q16790 2/20 0.38
CA14 Q9ULX7 2/20 0.38
CA5B Q9Y2D0 2/20 0.38
TSHR P16473 1/20 0.38
HTR1A P08908 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6770597 0.83 ADRB2 (0.41) KDM4EGAAMAPTALDH1A1CA2
SCHEMBL9860652 0.81 TAAR1 (0.47) KDM4EGAAMAPTALDH1A1ADRB2
SCHEMBL4720461 0.80 ALDH1A1 (0.52) KDM4EGAAMAPTALDH1A1ALOX5
SCHEMBL22288170 0.80 KDM4E (0.52) KDM4EGAAMAPTALDH1A1ALOX5
SCHEMBL14675474 0.79 SKP2 (0.48) MAPTALDH1A1ALOX5CA2ADRB2
SCHEMBL1299504 0.78 GAA (0.54) KDM4EGAAMAPTALDH1A1CA2
SCHEMBL17926089 0.77 FFAR1 (0.54) ALDH1A1CA2CA1POLB
SCHEMBL5212328 0.77 KDM4E (0.65) KDM4EGAAMAPTALDH1A1ALOX5
SCHEMBL4668334 0.77 KDM4E (0.65) KDM4EGAAMAPTALDH1A1ALOX5
SCHEMBL1853049 0.76 LOXL2 (0.44) KDM4EGAAMAPTCA2ADRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6951848-B2 Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor MILLENNIUM PHARMACEUTICALS, INC., (US) 2005-10-04 US disclosed
US-20050075348-A1 Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-04-07 US disclosed
EP-1377549-A1 FUNCTIONALIZED HETEROCYCLES AS MODULATORS OF CHEMOKINE RECEPTOR FUNCTION AND METHODS OF USE THEREFOR Millennium Pharmaceuticals, Inc. (US) 2004-01-07 EP disclosed
US-20030064991-A1 Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor MILLENNIUM PHARMACEUTICALS, INC. 2003-04-03 US disclosed
WO-2002072549-A1 FUNCTIONALIZED HETEROCYCLES AS MODULATORS OF CHEMOKINE RECEPTOR FUNCTION AND METHODS OF USE THEREFOR MILLENNIUM PHARMACEUTICALS, INC. (US) 2002-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030064991-A1 Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor ACKR3, CCR5, CXCR4 KDM4E 3859/4885GAA 3980/4885MAPT 4780/4885
US-20050075348-A1 Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor ACKR3, CCR5, CXCR4 KDM4E 3850/4885GAA 3668/4885MAPT 4789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.